Market Research Report
COVID-19 Pandemic and Rising Prevalence of Respiratory Disorders Catapult Growth in Global Extracorporeal Membrane Oxygenation (ECMO) Market
|Published by||Frost & Sullivan||Product code||987573|
|Published||Content info||81 Pages
Delivery time: 1-2 business days
|COVID-19 Pandemic and Rising Prevalence of Respiratory Disorders Catapult Growth in Global Extracorporeal Membrane Oxygenation (ECMO) Market|
|Published: December 24, 2020||Content info: 81 Pages||
Next-generation Devices Improving Survival and Workflow Efficiencies Uncovering New Growth Opportunities
Extracorporeal membrane oxygenation (ECMO) therapy has been in the limelight during the recent COVID-19 pandemic. This was due to its live-saving importance by improving the oxygenation, while providing pulmonary tissues adequate healing time, in patients suffering from acute respiratory distress syndrome (ARDS) caused by the viral infection. However, ECMO therapy had started gaining wider acceptance among critical care physicians post the 2009 influenza A (H1N1) pandemic. The driver was the consecutive generation of clinical trial evidence and multiple research studies proving its benefits to respiratory failure compared to conventional ventilation.
The ECMO market is expected to grow gradually, in mid-single digits. This is in the backdrop of increasing chronic obstructive pulmonary disease (COPD) cases and mainstream ECMO therapy adoption due to its beneficial role as a bridge to recovery, transplant, or ventricular assist device (VAD) for cardiopulmonary conditions. Other major factors driving ECMO adoption are currently low market penetration or installed base, higher incidences of key indications for ECMO therapy, advancements in technology, and poor outcomes from conventional therapies like mechanical ventilation. Survival rates with ECMO therapy have improved due to advancements in simplified circuit designs, specifically in oxygenators and blood pumps to enhance gas exchange, minimize hemolysis, and prevent clotting and bleeding risks; and the introduction of standardized protocols in high-volume ECMO centers with dedicated capabilities.
The market is concentrated with very few established participants, like Medtronic, Getinge, LivaNova and Terumo, along with emerging challengers, like Xenios (Fresenius Medical), Eurosets, Spectrum Medical, and OriGen Biomedical. There are also several disruptive participants, like ALung Technologies and Hemovent, with newly launched products. Established Tier I participants, like Medtronic, Terumo, and Getinge, are competitively positioned in the specialized components space. However, the market is transforming toward offering integrated systems with advanced monitoring capabilities due to greater emphasis on safety, simplification and compactness, and ease of usage. Though the ECMO market has not seen fierce inorganic growth strategies, there have been a few notable ones, like the Fresenius Medical-Xenios deal in 2016, LivaNova-TandemLife deal in 2019, and Abiomed-Breethe deal in 2020.